Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus

CompletedOBSERVATIONAL
Enrollment

212

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

June 25, 2024

Study Completion Date

June 25, 2025

Conditions
Diabetes Mellitus Type 2
Interventions
DRUG

Oral semaglutide

Starting dose 3 mg for a month, followed by 7 mg for a month increased up to 14 mg a month

DRUG

subcutaneous semaglutide

subcutaneous semaglutide can be started at 0,25 mg a week for a month, to be increased at 0,5 mg a week, up to 1 mg a week

Trial Locations (1)

90127

Policlinico Paolo Giaccone, Palermo

All Listed Sponsors
lead

University of Palermo

OTHER

NCT07056803 - Oral vs. Subcutaneous Semaglutide in Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter